Skip to main content
Log in

Everolimus beim metastasierten hormonrezeptorpositiven Mammakarzinom

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Burstein HJ (2011) Novel agents and future directions for refractory breast cacner. Semin Oncol 38(Suppl 2):17–24

    Article  Google Scholar 

  2. Efeyan A, Sabatini DM (2010) mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22:169–76

    Article  PubMed  CAS  Google Scholar 

  3. Baselga J, Semiglazov V, Dam P van et al (2009) Phase 2 randomized study of neoadjuvant everolimus plus letrozol compared with placebo plus letrozol in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630–2637

    Article  PubMed  CAS  Google Scholar 

  4. Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C. Richter-Ehrenstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richter-Ehrenstein, C. Everolimus beim metastasierten hormonrezeptorpositiven Mammakarzinom. Onkologe 18, 435–437 (2012). https://doi.org/10.1007/s00761-012-2251-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-012-2251-9

Navigation